Questcor Pharmaceuticals Upgraded by TheStreet to Buy (QCOR)
Questcor Pharmaceuticals (NASDAQ: QCOR) traded up 1.02% on Thursday, hitting $32.69. Questcor Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $58.91. The stock’s 50-day moving average is currently $29.23. The company has a market cap of $1.888 billion and a price-to-earnings ratio of 10.31.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, April 30th. Stockholders of record on Monday, April 22nd will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date of this dividend is Thursday, April 18th. This is a boost from Questcor Pharmaceuticals’s previous quarterly dividend of $0.20.
Other equities research analysts have also recently issued reports about the stock. Analysts at Ladenburg Thalmann raised their price target on shares of Questcor Pharmaceuticals from $33.00 to $38.00 in a research note to investors on Wednesday, February 27th. They now have a buy rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Questcor Pharmaceuticals from $30.00 to $38.00 in a research note to investors on Wednesday, February 27th. They now have a buy rating on the stock. Finally, analysts at Janney Montgomery Scott initiated coverage on shares of Questcor Pharmaceuticals in a research note to investors on Thursday, February 21st. They set a buy rating and a $40.00 price target on the stock.
Seven research analysts have rated the stock with a buy rating, and three have issued a hold rating to the company’s stock. The company presently has an average rating of overweight and a consensus target price of $45.38.
Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company’s primary product is H.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.